Release Date: February 11, 2022
Expiration Date: February 11, 2023
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in dermatology to discuss newer treatments for patients with psoriasis. Psoriasis has no clearly defined cause or cure, but it does have a significant impact on quality of life. It is now recognized as a systemic disease associated with psoriatic arthritis and other serious comorbidities. The critical pathogenic pathway in psoriasis is considered to be the interleukin (IL)-23/IL-17 axis. This pathway uses the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway to transduce intracellular signals. Although small molecules that block the JAK/STAT pathway and reduce inflammation have been developed, their relative nonspecific nature and toxicity have hindered their use in patients with psoriasis. Current research is focused on tyrosine kinase 2 (TYK2) inhibitors, which have more favorable efficacy and safety profiles.
In this CME activity, a panel of experts discusses treatment options for patients with psoriasis, focusing on newer TYK2 inhibitors. The program includes a short, animated video that illustrates the mechanism of action of newer therapeutic agents in psoriasis.
This educational activity is an archive of the live virtual symposium, held on January 25, 2022.
Target Audience
This educational activity is directed toward the dermatologists, nurse practitioners, and physician assistants who treat patients with dermatologic conditions.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the etiology, pathophysiology, and important considerations in the diagnosis of psoriasis.
- Evaluate the latest data on the efficacy, safety, dosing, and administration of novel TYK2 inhibitors for patients with psoriasis.
- Integrate targeted TYK2 inhibitors into the treatment of psoriasis.
April W. Armstrong, MD, MPH
Professor of Dermatology
Associate Dean for Clinical Research
Keck School of Medicine at USC
University of Southern California
Los Angeles, CA
Disclosures: Grant/Research support: Bristol Myers Squibb, Dermavant Sciences,
Dermira, LEO Pharma, Eli Lilly and Company, Pfizer, UCB. Consultant: AbbVie, ASLAN Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant Sciences, Dermira, EPI Health, Incyte, Janssen, LEO Pharma, Lilly, MS Pharma, Novartis, Ortho Dermatologics, Parexel, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sun Pharmaceutical Industries, UCB.
James Q. Del Rosso, DO, FAOCD
Research Director/Principal Investigator
JDR Dermatology Research
Las Vegas, NV
Senior Vice President of Clinical Research and Strategic Development
Advanced Dermatology & Cosmetic Surgery
Maitland, FL
Disclosures: Grant/Research support: Aclaris Therapeutics, Almirall, Amgen Oncology (Celgene), AnaptysBio, Arcutis Biotherapeutics, Athene, Bausch Health (Ortho Dermatology), Biorasi, Botanix Pharmaceuticals, Brickell Biotech, Cara Therapeutics, Cassiopea SpA, Dermavant Sciences, EPI Health, Galderma, Genentech, Incyte, Janssen, LEO Pharma, Eli Lilly and Company (Dermira), Novan, Pfizer, Ralexar Therapeutics, Regeneron Pharmaceuticals, Sol-Gel Technologies, Sun Pharmaceutical Industries, UCB, VYNE Therapeutics. Consultant: AbbVie, Aclaris Therapeutics, Almirall, Amgen Oncology, Arcutis Biotherapeutics, Bausch Health (Ortho Dermatologics), Biofrontera, BioPharmX, Blue Creek Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Cassiopea SpA, Dermata Therapeutics, Dermavant Sciences, Encore Pharmaceuticals, EPI Health, Evommune, Ferndale Pharmaceuticals, Galderma, Sanofi Genzyme, Incyte, Jem Health, La Roche-Posay, LEO Pharma, Eli Lilly and Company (Dermira), MC2 Therapeutics, Novan, Pfizer, Regeneron Pharmaceuticals, Sanofi-Sente, Sol-Gel Technologies, Sonoma (IntraDerm), Sun Pharmaceutical Industries, UCB, Verrica Pharmaceuticals, VYNE Therapeutics. Speaker’s bureau: Aclaris Therapeutics, Almirall, Amgen Oncology, Bausch Health (Ortho Dermatologics); Biofrontera, BioPharmX, Bristol Myers Squibb, Encore Pharmaceuticals, EPI Health, Ferndale Pharmaceuticals, Galderma, Genentech, Incyte, Jem Health, LEO Pharma, Eli Lilly and Company (Dermira), Pfizer, Regeneron Pharmaceuticals, Sanofi-Genzyme, Sun Pharmaceutical Industries, UCB, Verrica Pharmaceuticals, VYNE Therapeutics.
Linda F. Stein Gold, MD
Director, Dermatology Clinical Research
Head, Division of Dermatology
Henry Ford Health System
Detroit, MI
Disclosures: Grant/Research support: AbbVie, Amgen Oncology, Arcutis Biotherapeutics, Bristol Myers Squibb, Denova Medical, Novartis, Pfizer, UCB. Consultant: AbbVie, Amgen Oncology, Arcutis Biotherapeutics, Bristol Myers Squibb, Denova Medical, Novartis, Pfizer, UCB. Speaker’s bureau: Amgen Oncology, Arcutis Biotherapeutics, Bristol Myers Squibb, Pfizer, UCB.
Disclosures/Disclaimers
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here